A novel therapeutic vaccine approach, targeting RANKL, prevents bone destruction in bone-related disorders.
Department of Orthopaedic Surgery, Faculty of Medicine, The University of Tokyo, 7-3-1 Hongo, Bunkyo-ku, Tokyo 113-0033, Japan.
Takuo
T
Juji
Marc
M
Hertz
Kazuhiro
K
Aoki
Daisuke
D
Horie
Keiichi
K
Ohya
Anand
A
Gautam
Søren
S
Mouritsen
Hiromi
H
Oda
Kozo
K
Nakamura
Sakae
S
Tanaka
D000818:Animals; D001172:Arthritis, Rheumatoid / Q000188:drug therapy; D018488:Bone Demineralization, Pathologic / Q000517:prevention & control; D001847:Bone Diseases / Q000503:physiopathology / Q000517:prevention & control*; D016723:Bone Remodeling / Q000502:physiology; D001862:Bone Resorption / Q000517:prevention & control; D002352:Carrier Proteins / Q000187:drug effects / Q000276:immunology* / Q000378:metabolism; D006023:Glycoproteins / Q000494:pharmacology / Q000627:therapeutic use*; D006801:Humans; D008562:Membrane Glycoproteins / Q000187:drug effects / Q000276:immunology* / Q000378:metabolism; D051379:Mice; D016328:NF-kappa B / Q000378:metabolism; D010010:Osteoclasts / Q000378:metabolism; D053244:Osteoprotegerin; D053245:RANK Ligand; D053246:Receptor Activator of Nuclear Factor-kappa B; D018160:Receptors, Cytoplasmic and Nuclear / Q000627:therapeutic use*; D018124:Receptors, Tumor Necrosis Factor; D014612:Vaccines / Q000494:pharmacology / Q000627:therapeutic use*
D002352:Carrier Proteins; D006023:Glycoproteins; D008562:Membrane Glycoproteins; D016328:NF-kappa B; D053244:Osteoprotegerin; D053245:RANK Ligand; D053246:Receptor Activator of Nuclear Factor-kappa B; D018160:Receptors, Cytoplasmic and Nuclear; D018124:Receptors, Tumor Necrosis Factor; C505686:TNFRSF11A protein, human; C506030:TNFRSF11B protein, human; C505688:TNFSF11 protein, human; C505687:Tnfrsf11a protein, mouse; C506031:Tnfrsf11b protein, mouse; C505689:Tnfsf11 protein, mouse; D014612:Vaccines